GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Royalty Pharma PLC (STU:RPD) » Definitions » Profitability Rank

Royalty Pharma (STU:RPD) Profitability Rank : 7 (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Royalty Pharma Profitability Rank?

Royalty Pharma has the Profitability Rank of 7.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

Royalty Pharma's Operating Margin % for the quarter that ended in Sep. 2024 was 130.17%. As of today, Royalty Pharma's Piotroski F-Score is 6.


Competitive Comparison of Royalty Pharma's Profitability Rank

For the Biotechnology subindustry, Royalty Pharma's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Royalty Pharma's Profitability Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Royalty Pharma's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Royalty Pharma's Profitability Rank falls into.



Royalty Pharma Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Royalty Pharma has the Profitability Rank of 7.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Royalty Pharma's Operating Margin % for the quarter that ended in Sep. 2024 is calculated as:

Operating Margin %=Operating Income (Q: Sep. 2024 ) / Revenue (Q: Sep. 2024 )
=662.302 / 508.786
=130.17 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Royalty Pharma has an F-score of 6 indicating the company's financial situation is typical for a stable company.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

Warning Sign:

Royalty Pharma PLC operating margin has been in a 5-year decline. The average rate of decline per year is -13.1%.

4. Consistency of the profitability

5. Predictability Rank


Royalty Pharma Profitability Rank Related Terms

Thank you for viewing the detailed overview of Royalty Pharma's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Royalty Pharma Business Description

Traded in Other Exchanges
Address
110 East 59th Street, New York, NY, USA, 10022
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Royalty Pharma Headlines